http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1295939-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94c8c4ae459da0599056335fd5888b21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66467fe5b0acf469afb972f300bcfb87 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576 |
| filingDate | 1987-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0850fa2963c1576a9fcb4279fc954f2 |
| publicationDate | 1992-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1295939-C |
| titleOfInvention | Method for the detection of pregnancy disorders |
| abstract | ABSTRACT OF THE DISCLOSURE The present invention relates to a method for determining pregnancy disorders by analysing a biological fluid sample. According to the method, an antigen consisting of a specific non-hormonal human-derived placental soluble protein is labelled by a radioactive iodine. The sample and a first antibody compatible with the placental antigen is incubated and to the product obtained is applied a second antibody attached to a solid composition. In the resulted precipitated complex the radioactivity is determined thus establishing the extent of pregnancy disorders. The best results are obtained when the protein to be labelled is present at a concentration of above 0.7 mg/ml. A preferred non-hormonal human-derived placental soluble protein is PP-13. The biological fluid sample is selected from blood, amniotic fluid or urine. |
| priorityDate | 1986-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.